机构名称：
¥ 1.0
Lausanne, Switzerland – April 4 th , 2024 – Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standard-of-care to cure cancer and infectious diseases, today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [选择性WEE1抑制剂]和Debio 0432 [选择性USP1抑制剂]在加利福尼亚州圣地亚哥举行的2024年度美国癌症研究协会（AACR）峰会上。
4月8日星期一新闻稿
主要关键词
相关文件推荐
